Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Journal Article (Clinical Trial;Journal Article;Multicenter Study)
BACKGROUND: Studies have shown that cigarette smokers constitute a substantial proportion of patients with acute coronary syndromes (ACS) and have platelet-rich coronary thrombi. We characterized the influence of smoking status on outcome of patients with ACS without persistent ST-segment elevation and tested the hypothesis that selective inhibition of the platelet glycoprotein IIb/IIIa receptor with eptifibatide would improve outcomes among cigarette smokers. METHODS: The study population included patients enrolled in the PURSUIT trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) with known smoking status presenting with ischemic chest pain
Full Text
Duke Authors
Cited Authors
- Hasdai, D; Holmes, DR; Criger, DA; Topol, EJ; Califf, RM; Wilcox, RG; Paolasso, E; Simoons, M; Deckers, J; Harrington, RA
Published Date
- March 2000
Published In
Volume / Issue
- 139 / 3
Start / End Page
- 454 - 460
PubMed ID
- 10689260
International Standard Serial Number (ISSN)
- 0002-8703
Digital Object Identifier (DOI)
- 10.1016/s0002-8703(00)90089-9
Language
- eng
Conference Location
- United States